Drug
Rilvegostomig clinical trials
Also written AZD2936.
Keep track of what changes. Save the rilvegostomig studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
28 studies that test it; most in 2025 (8)
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2020 | 1 |
| 2021 | 3 |
| 2022 | 1 |
| 2023 | 4 |
| 2024 | 7 |
| 2025 | 8 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 23 · Other 5
AstraZeneca (21) · Presage Biosciences (2) · University Health Network, Toronto (2) · Vall d'Hebron Institute of Oncology (1) · CCTU- Cancer Theme (1) · Jeeyun Lee (1)
Often tested with
Tested in the same studies.
Volrustomig (7) · Cisplatin (5) · Datopotamab deruxtecan (4) · Trastuzumab deruxtecan (4) · Pembrolizumab (3) · Durvalumab (3) · Pemetrexed (3) · Carboplatin (3)
Studies
Open first, then newest update. How each study uses rilvegostomig is read from its arms, and is right about nine times in ten.
Testing it · 28
- Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung CancerRecruitingPhase 2AstraZenecaNCT05061550Written as Rilvegostomig
- A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric CancerRecruitingPhase 3AstraZenecaNCT06764875Written as Rilvegostomig
- Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2RecruitingPhase 3AstraZenecaNCT07431281Written as Rilvegostomig
- A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid MalignanciesRecruitingPhase 1/2AstraZenecaNCT05123482Written as AZD8205 and AZD2936 (Rilvegostomig)
- Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract CancerRecruitingPhase 3AstraZenecaNCT06467357Written as Rilvegostomig
- Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular CarcinomaRecruitingPhase 3AstraZenecaNCT06921785Written as Rilvegostomig
- DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial CancerRecruitingPhase 3AstraZenecaNCT06989112Written as Rilvegostomig
- Molecular Residual Disease Interception in Locoregionally-Advanced High Risk HPV+ and HPV- HNSCCRecruitingPhase 2University Health Network, TorontoNCT05414032Written as AZD2936
- A Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Rilvegostomig in Adult Participants With Advanced Solid Tumors Previously Treated With Standard of Care TherapyRecruitingPhase 1AstraZenecaNCT07161414Written as IV Rilvegostomig
- A Platform Study in Non-Small Cell Lung Cancer (NSCLC)RecruitingPhase 1/2AstraZenecaNCT06996782Written as Rilvegostomig
- A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)RecruitingPhase 3AstraZenecaNCT07221253Written as Rilvegostomig
- WIRE - Novel Treatments in Renal Cell CancerRecruitingPhase 2CCTU- Cancer ThemeNCT03741426Written as Rilvegostomig
- A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung CancerRecruitingPhase 3AstraZenecaNCT06868277Written as Rilvegostomig
- Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic AlterationsRecruitingPhase 3AstraZenecaNCT06357533Written as Rilvegostomig
- A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLCRecruitingPhase 3AstraZenecaNCT06627647Written as Rilvegostomig
- A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)RecruitingPhase 3AstraZenecaNCT06692738Written as Rilvegostomig
- Local and Systemic Immune Modulation by Rilvegostomig (AZD2936) in the Treatment of Advanced Gastric Cancer (RILVE Project)Not yet recruitingPhase 2Vall d'Hebron Institute of OncologyNCT07788664Written as Rilvegostomig
- An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUCRecruitingPhase 3AstraZenecaNCT07720284Written as Rilvegostomig
- Perioperative Therapies in Locally Advanced Unresectable Gastric CancerRecruitingPhase 2Jeeyun LeeNCT06630130Written as Rilvegostomig
- Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction AdenocarcinomaRecruitingPhase 2AstraZenecaNCT05702229Written as Rilvegostomig
See all 28 studies that test rilvegostomig →
Given in every arm · 8 — rilvegostomig is usual care beside what is tested
- A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal AdenocarcinomaRecruitingPhase 2AstraZenecaNCT07069712Written as Rilvegostomig
- A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)RecruitingPhase 2AstraZenecaNCT07098338Written as Rilvegostomig
- A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid TumorsRecruitingPhase 1/2AstraZenecaNCT07115043Written as rilvegostomig
- Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid TumorsRecruitingPhase 1/2AstraZenecaNCT06005493Written as AZD2936
- Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)RecruitingPhase 2AstraZenecaNCT05489211Written as Rilvegostomig
- Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLCRecruitingPhase 1AstraZenecaNCT04686305Written as Rilvegostomig
- Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)Active, not recruitingPhase 2AstraZenecaNCT04379596Written as Rilvegostomig
- Phase 1b Study of Dato-DXd in Combination With Immunotherapy With or Without Carboplatin in Advanced or Metastatic Non-Small Cell Lung CancerActive, not recruitingPhase 1AstraZenecaNCT04612751Written as AZD2936
Codes
What other systems call rilvegostomig · ClinicalTrials.gg INT018617
- UNII (FDA) YSL2GUT2Q8RILVEGOSTOMIGOne source FDA
- NCI Thesaurus C188211RilvegostomigOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | YSL2GUT2Q8 | RILVEGOSTOMIG | One source FDA |
| NCI Thesaurus | C188211 | Rilvegostomig | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.